Aldafermin
Primary Biliary Cholangitis
NGM Biopharmaceuticals, Incprotein_peptidePhase 2Dormant
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 47/ 100
- Competitive Position
- 95/ 100
Competitive context
19 Active assets in the Primary Biliary Cholangitis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ursodeoxycholic Acid Xijing Hospital of Digestive Diseases | Phase 4 | A |
Fenofibrate Xijing Hospital of Digestive Diseases | Phase 3 | BB |
Saroglitazar Zydus Therapeutics Inc. | Phase 3 | BB |
Obeticholic Acid Intercept Pharmaceuticals | Phase 3 | BB |
cs0159 Cascade Pharmaceuticals, Inc | Phase 3 | BB |
View all 49 →
Same molecule, other indications
Aldafermin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →